Literature DB >> 22365159

Cardio-renal syndrome type 2: epidemiology, pathophysiology, and treatment.

Preeti Jois1, Alexandre Mebazaa.   

Abstract

Cardiac and kidney disease are becoming increasingly more prevalent in the population, and may exist concurrently. One of the most important comorbidities in heart failure is renal dysfunction. The pathophysiology of cardio-renal syndromes is complicated, and has been divided into five categories. Cardio-Renal syndrome type 2 is described by chronic cardiac abnormalities resulting in impaired renal function. It is important to recognize this entity and to understand the pathophysiology underlying the cardiac and renal disorders to distinguish best treatment practices. The success in improved outcomes lies in optimization of heart failure therapies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365159     DOI: 10.1016/j.semnephrol.2011.11.004

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  9 in total

Review 1.  Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys.

Authors:  Kaushik P Patel; Kenichi Katsurada; Hong Zheng
Journal:  Circ Res       Date:  2022-05-12       Impact factor: 23.213

2.  Unforeseen renal pathological findings in a patient with type 2 cardiorenal syndrome who died after 4 years of continuous ambulatory peritoneal dialysis.

Authors:  Masaru Matsui; Satoshi Okayama; Kenichi Samejima; Yoshihiko Saito
Journal:  BMJ Case Rep       Date:  2013-01-24

Review 3.  Nonuremic indication for peritoneal dialysis for refractory heart failure in cardiorenal syndrome type II: review and perspective.

Authors:  Masaaki Nakayama
Journal:  Perit Dial Int       Date:  2013 Jan-Feb       Impact factor: 1.756

4.  Prevalence, predictors, and outcomes of cardiorenal syndrome in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry.

Authors:  Ahmad Kaddourah; Stuart L Goldstein; Steven E Lipshultz; James D Wilkinson; Lynn A Sleeper; Minmin Lu; Steven D Colan; Jeffrey A Towbin; Scott I Aydin; Joseph Rossano; Melanie D Everitt; Jeffrey G Gossett; Paolo Rusconi; Paul F Kantor; Rakesh K Singh; John L Jefferies
Journal:  Pediatr Nephrol       Date:  2015-07-26       Impact factor: 3.714

Review 5.  Co-morbidities in heart failure.

Authors:  Vincent M van Deursen; Kevin Damman; Peter van der Meer; Peter J Wijkstra; Gert-Jan Luijckx; Andre van Beek; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

6.  Time Course of the Effects of Buxin Yishen Decoction in Promoting Heart Function and Inhibiting the Progression of Renal Fibrosis in Myocardial Infarction Caused Type 2 Cardiorenal Syndrome Rats.

Authors:  Qi Qiu; Jinglin Cao; Yong Wang; Yunnan Zhang; Yun Wei; Xiaoyan Hao; Yu Mu; Yang Lin
Journal:  Front Pharmacol       Date:  2019-10-23       Impact factor: 5.810

7.  Acute kidney injury and acute kidney recovery following Transcatheter Aortic Valve Replacement.

Authors:  Marilou Peillex; Benjamin Marchandot; Kensuke Matsushita; Eric Prinz; Sebastien Hess; Antje Reydel; Marion Kibler; Adrien Carmona; Antonin Trimaille; Joe Heger; Hélène Petit-Eisenmann; Annie Trinh; Laurence Jesel; Patrick Ohlmann; Olivier Morel
Journal:  PLoS One       Date:  2021-08-10       Impact factor: 3.240

Review 8.  Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome.

Authors:  Jois Preeti; Mebazaa Alexandre; Iyngkaran Pupalan; Thomas C Merlin; Ronco Claudio
Journal:  Curr Cardiol Rev       Date:  2016

9.  Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome.

Authors:  Yi Liang; WenJun Zhao; Yan Wang; GuangPing Fu; QingQuan Li; XuChen Min; YiFang Guo
Journal:  Sci Rep       Date:  2020-03-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.